Inpharma 1641 - 7 Jun 2008

Placental expanded cells: modelfor future success in IBD?

A placental expanded cell therapeutic [PLX-IBD] wassignificantly more effective than current standard-of-care therapy for inflammatory bowel disease (IBD), in ananimal model of this disorder. This product, whichcomprises placental-derived mesenchymal stromalcells, is being developed by Pluristem Therapeutics aspart of a preclinical development programme of celltherapeutics for degenerative, ischaemic andautoimmune indications. In mouse and rat models ofIBD, IV administration of PLX-IBD was associated withsignificantly reduced macroscopic and microscopiccolon lesions, compared with placebo and standardtherapy.Pluristem Therapeutics Inc. Pluristem Demonstrates the Potential of Its PLX Cellsto Treat Crohn’s Disease and Ulcerative Colitis. Media Release : 28 May 2008.Available from: URL: http://www.pluristem.com 809089421

1

Inpharma 7 Jun 2008 No. 16411173-8324/10/1641-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved